Advert - GlaxoSmithKline UK Limited – Case AUTH/3432/12/20

Promotion of respiratory medicines

 

GlaxoSmithKline was ruled in breach of the following clauses of the 2019 Code in relation to the promotion of its respiratory medicines, Trelegy (fluticasone/umeclidinium/vilanterol), Anoro (umeclidinium/vilanterol), Incruse (umeclidinium) and Relvar (fluticasone/vilanterol):

 

Clause 2           - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 3.2        - Promotion inconsistent with the summary of product characteristics (SPC)

Clause 4.3        - Failing to include the non-proprietary names next to the most prominent display of the brand name

Clause 4.9        - Failing to include information about how to report adverse events

Clause 4.10      - Failing to include an inverted black triangle for relevant products

Clause 9.1        - Failing to maintain high standards

Clause 14.1      - Failing to certify the final form of promotional material

Clause 26.3      - Failing to include information about how to report adverse events on material for patients

Advert